NO124600B - - Google Patents

Download PDF

Info

Publication number: NO124600B
Authority: NO; Norway
Prior art keywords: pyridyl; compound; prepared; hydroxyphenyl; isonicotinoyl
Prior art date: 1968-10-04

Application number

NO3956/69A

Other languages

English (en)

Norwegian (no)

Inventor

F Binon

J Beiler

Original Assignee

Labaz Soc Anonyme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1968-10-04

Filing date

1969-10-03

Publication date

1972-05-08

1968-10-04 Priority claimed from GB47297/68A external-priority patent/GB1245283A/en

1969-10-03 Application filed by Labaz Soc Anonyme filed Critical Labaz Soc Anonyme

1972-05-08 Publication of NO124600B publication Critical patent/NO124600B/no

Links

238000000034 method Methods 0.000 claims description 15
-1 hydroxy, methyl Chemical group 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
FMDGBNOKORNXFS-UHFFFAOYSA-N (2-propan-2-yl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CC(C)C=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 FMDGBNOKORNXFS-UHFFFAOYSA-N 0.000 claims description 5
150000003217 pyrazoles Chemical class 0.000 claims description 5
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 4
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
MFOAZWWJQXMCGY-UHFFFAOYSA-N bis(1-benzofuran-3-yl)methanone Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4OC=3)=O)=COC2=C1 MFOAZWWJQXMCGY-UHFFFAOYSA-N 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Chemical group 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical group COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 claims description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 claims 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 50
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
241000700605 Viruses Species 0.000 description 17
241001465754 Metazoa Species 0.000 description 15
238000012360 testing method Methods 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
238000002474 experimental method Methods 0.000 description 12
241000709661 Enterovirus Species 0.000 description 11
FEAWBEXORWNEBV-UHFFFAOYSA-N 2-(5-ethyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC=CC=C1O FEAWBEXORWNEBV-UHFFFAOYSA-N 0.000 description 10
239000012895 dilution Substances 0.000 description 10
238000010790 dilution Methods 0.000 description 10
239000000725 suspension Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
235000013601 eggs Nutrition 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
239000000243 solution Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
XPFPMBGGYRSASS-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 XPFPMBGGYRSASS-UHFFFAOYSA-N 0.000 description 5
PTAKNRJSEKAGBP-UHFFFAOYSA-N (2-ethyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 PTAKNRJSEKAGBP-UHFFFAOYSA-N 0.000 description 5
DYIVYCPEISTLRG-UHFFFAOYSA-N 2-(3-ethyl-1-methyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCC1=NN(C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O DYIVYCPEISTLRG-UHFFFAOYSA-N 0.000 description 5
229940126062 Compound A Drugs 0.000 description 5
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
241000712461 unidentified influenza virus Species 0.000 description 5
MVHXBACVHWNPDE-UHFFFAOYSA-N (2-methyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CC=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 MVHXBACVHWNPDE-UHFFFAOYSA-N 0.000 description 4
OCWNCBPLBLLYDT-UHFFFAOYSA-N 2-(5-propan-2-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CC(C)C=1NN=C(C=2C=CN=CC=2)C=1C1=CC=CC=C1O OCWNCBPLBLLYDT-UHFFFAOYSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 4
KJAQRHMKLVGSCG-UHFFFAOYSA-N propan-2-ylhydrazine Chemical compound CC(C)NN KJAQRHMKLVGSCG-UHFFFAOYSA-N 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
HYHWRZLPFDSXAU-UHFFFAOYSA-N 4-methoxy-2-(5-methyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound COC1=CC=C(O)C(C=2C(=NNC=2C)C=2C=CN=CC=2)=C1 HYHWRZLPFDSXAU-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
XKLVLDXNZDIDKQ-UHFFFAOYSA-N butylhydrazine Chemical compound CCCCNN XKLVLDXNZDIDKQ-UHFFFAOYSA-N 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000011835 investigation Methods 0.000 description 3
210000005084 renal tissue Anatomy 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
206010023332 keratitis Diseases 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
WHIMZWTZGMGBRW-UHFFFAOYSA-N (2-ethyl-5-methyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCC=1OC2=CC=C(C)C=C2C=1C(=O)C1=CC=NC=C1 WHIMZWTZGMGBRW-UHFFFAOYSA-N 0.000 description 1
LUKWGNUVKFXOIC-UHFFFAOYSA-N (2-propyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 LUKWGNUVKFXOIC-UHFFFAOYSA-N 0.000 description 1
PSAZRCUOVITLAG-UHFFFAOYSA-N (5-bromo-2-ethyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCC=1OC2=CC=C(Br)C=C2C=1C(=O)C1=CC=NC=C1 PSAZRCUOVITLAG-UHFFFAOYSA-N 0.000 description 1
AKXOKNCGPBQLCG-UHFFFAOYSA-N (5-chloro-2-ethyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCC=1OC2=CC=C(Cl)C=C2C=1C(=O)C1=CC=NC=C1 AKXOKNCGPBQLCG-UHFFFAOYSA-N 0.000 description 1
INFMMIHAIGZCKS-UHFFFAOYSA-N (5-methoxy-2-methyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound C12=CC(OC)=CC=C2OC(C)=C1C(=O)C1=CC=NC=C1 INFMMIHAIGZCKS-UHFFFAOYSA-N 0.000 description 1
SHOQNGNCKXPZGH-UHFFFAOYSA-N 1-benzofuran-3-yl(pyridin-4-yl)methanone Chemical compound C=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 SHOQNGNCKXPZGH-UHFFFAOYSA-N 0.000 description 1
NEFSEMZHKBUTIB-UHFFFAOYSA-N 2-(1,3-diethyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCC1=NN(CC)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O NEFSEMZHKBUTIB-UHFFFAOYSA-N 0.000 description 1
KGIRNTGMGIXVAU-UHFFFAOYSA-N 2-(1,3-dimethyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CC1=NN(C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O KGIRNTGMGIXVAU-UHFFFAOYSA-N 0.000 description 1
ZFTLDFOVDXCCSA-UHFFFAOYSA-N 2-(1-butyl-3-ethyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCCN1N=C(CC)C(C=2C(=CC=CC=2)O)=C1C1=CC=NC=C1 ZFTLDFOVDXCCSA-UHFFFAOYSA-N 0.000 description 1
HVKMTODQBOIBMD-UHFFFAOYSA-N 2-(1-butyl-3-propan-2-yl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCCN1N=C(C(C)C)C(C=2C(=CC=CC=2)O)=C1C1=CC=NC=C1 HVKMTODQBOIBMD-UHFFFAOYSA-N 0.000 description 1
PNEPIGKWZUFCLB-UHFFFAOYSA-N 2-(1-ethyl-3-methyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCN1N=C(C)C(C=2C(=CC=CC=2)O)=C1C1=CC=NC=C1 PNEPIGKWZUFCLB-UHFFFAOYSA-N 0.000 description 1
CISPPGBBAMENMH-UHFFFAOYSA-N 2-(3-butyl-1-ethyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCCC1=NN(CC)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O CISPPGBBAMENMH-UHFFFAOYSA-N 0.000 description 1
ZAKHXMKPKBMWEW-UHFFFAOYSA-N 2-(3-butyl-1-methyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCCC1=NN(C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O ZAKHXMKPKBMWEW-UHFFFAOYSA-N 0.000 description 1
LWJFLZFOXVFSHD-UHFFFAOYSA-N 2-(3-butyl-1-propan-2-yl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCCC1=NN(C(C)C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O LWJFLZFOXVFSHD-UHFFFAOYSA-N 0.000 description 1
GFNCZMXXAXDLNB-UHFFFAOYSA-N 2-(3-ethyl-1-propan-2-yl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCC1=NN(C(C)C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O GFNCZMXXAXDLNB-UHFFFAOYSA-N 0.000 description 1
UOGLXWJCDYDKLA-UHFFFAOYSA-N 2-(3-ethyl-1-propyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCN1N=C(CC)C(C=2C(=CC=CC=2)O)=C1C1=CC=NC=C1 UOGLXWJCDYDKLA-UHFFFAOYSA-N 0.000 description 1
LDMMBSBOVYZKFB-UHFFFAOYSA-N 2-(3-methyl-1-propan-2-yl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CC(C)N1N=C(C)C(C=2C(=CC=CC=2)O)=C1C1=CC=NC=C1 LDMMBSBOVYZKFB-UHFFFAOYSA-N 0.000 description 1
LCRFIIFVHGZPHC-UHFFFAOYSA-N 2-(5-butyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CCCCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC=CC=C1O LCRFIIFVHGZPHC-UHFFFAOYSA-N 0.000 description 1
KZPRJNHBNJTPNO-UHFFFAOYSA-N 2-(5-ethyl-3-pyridin-4-yl-1H-pyrazol-4-yl)-4-methylphenol Chemical compound CCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC(C)=CC=C1O KZPRJNHBNJTPNO-UHFFFAOYSA-N 0.000 description 1
FIXVVFJQLXMFCT-UHFFFAOYSA-N 2-(5-methyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CC=1NN=C(C=2C=CN=CC=2)C=1C1=CC=CC=C1O FIXVVFJQLXMFCT-UHFFFAOYSA-N 0.000 description 1
HXXWGVSPETWGDE-UHFFFAOYSA-N 2-(5-propyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CCCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC=CC=C1O HXXWGVSPETWGDE-UHFFFAOYSA-N 0.000 description 1
OKOXZGVCTGVUCK-UHFFFAOYSA-N 2-(5-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound OC1=CC=CC=C1C1=CNN=C1C1=CC=NC=C1 OKOXZGVCTGVUCK-UHFFFAOYSA-N 0.000 description 1
OTVPSYVTWJJRCE-UHFFFAOYSA-N 2-[1,3-di(propan-2-yl)-5-pyridin-4-ylpyrazol-4-yl]phenol Chemical compound CC(C)C1=NN(C(C)C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O OTVPSYVTWJJRCE-UHFFFAOYSA-N 0.000 description 1
OZTVSCCOSAASBJ-UHFFFAOYSA-N 4-bromo-2-(5-ethyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC(Br)=CC=C1O OZTVSCCOSAASBJ-UHFFFAOYSA-N 0.000 description 1
UUVZXPYBDRQFHU-UHFFFAOYSA-N 4-chloro-2-(5-ethyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC(Cl)=CC=C1O UUVZXPYBDRQFHU-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010068319 Oropharyngeal pain Diseases 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
208000036071 Rhinorrhea Diseases 0.000 description 1
206010039101 Rhinorrhoea Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
208000027744 congestion Diseases 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
UKPBXIFLSVLDPA-UHFFFAOYSA-N propylhydrazine Chemical compound CCCNN UKPBXIFLSVLDPA-UHFFFAOYSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
206010041232 sneezing Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO3956/69A 1968-10-04 1969-10-03 NO124600B (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB47297/68A GB1245283A (en)	1968-10-04	1968-10-04	Pyrazole derivatives

Publications (1)

Publication Number	Publication Date
NO124600B true NO124600B (de)	1972-05-08

Family

ID=10444445

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO3956/69A NO124600B (de)	1968-10-04	1969-10-03

Country Status (8)

Country	Link
AT (1)	AT286981B (de)
BR (1)	BR6912660D0 (de)
DK (1)	DK119769B (de)
ES (1)	ES372202A1 (de)
NL (1)	NL161451C (de)
NO (1)	NO124600B (de)
SE (1)	SE349032B (de)
YU (1)	YU33195B (de)

0
- NL NL6914957.A patent/NL161451C/xx active
1969
- 1969-09-24 BR BR212660/69A patent/BR6912660D0/pt unknown
- 1969-10-01 SE SE13538/69A patent/SE349032B/xx unknown
- 1969-10-03 DK DK527569AA patent/DK119769B/da unknown
- 1969-10-03 YU YU2486/69A patent/YU33195B/xx unknown
- 1969-10-03 NO NO3956/69A patent/NO124600B/no unknown
- 1969-10-04 ES ES372202A patent/ES372202A1/es not_active Expired
- 1969-10-06 AT AT941069A patent/AT286981B/de active

Also Published As

Publication number	Publication date
SE349032B (de)	1972-09-18
DK119769B (da)	1971-02-22
BR6912660D0 (pt)	1973-04-19
NL161451C (nl)
YU248669A (en)	1975-12-31
AT286981B (de)	1971-01-11
YU33195B (en)	1976-06-30
ES372202A1 (es)	1971-09-16

Publication	Publication Date	Title
US4339445A (en)	1982-07-13	Method for combating virus infection
CN113181339A (zh)	2021-07-30	一种醛基类化合物的药物用途
DK169657B1 (da)	1995-01-09	Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider
JP2009525338A (ja)	2009-07-09	抗アレナウイルス化合物
PL115117B1 (en)	1981-03-31	Method of manufacture of novel carbonyl substituted 1-sulfonylobenzimidazoles
US4990537A (en)	1991-02-05	Anti influenza agent
US4000281A (en)	1976-12-28	Pyrazole derivatives
JPS5962574A (ja)	1984-04-10	トリアゾ−ル系抗真菌剤
US4340760A (en)	1982-07-20	Monophenylamine derivatives
CN105622596A (zh)	2016-06-01	含有烷氧亚胺基氮杂环片段的苯并噻嗪-4-酮类化合物及其制备方法
CA2570577A1 (en)	2006-08-17	Anti-viral uses of borinic acid complexes
CN109503510B (zh)	2020-07-03	一种防龋抗菌的噻唑类化合物及其制备方法
JPS58914A (ja)	1983-01-06	抗ウイルス作用を有する医薬組成物
US4755601A (en)	1988-07-05	Nonyl prenyl-N heterocyclics
NL8803092A (nl)	1989-07-17	Tromethaminezout van 1-methyl-beta-oxo-alfa-(fenylcarbamoyl)-2-pyrroolpropionitril.
Ukrainets et al.	2008	4-Hydroxy-2-quinolones 139. Synthesis, structure, and antiviral activity of NR-amides of 2-hydroxy-4-oxo-4H-pyrido [1, 2-a] pyrimidine-3-carboxylic acids
JPS5883620A (ja)	1983-05-19	薬剤としての４−フエニル−４−オキソ−２−ブテン酸のある種の誘導体及びそれを含有する組成物
JPS63170366A (ja)	1988-07-14	イミダゾール誘導体、その製造方法及びこれを含有する抗菌剤
SU1616519A3 (ru)	1990-12-23	Способ получени 1,3,4-тиадиазол-2-цианамида или его фармацевтически приемлемых солей
GB2065111A (en)	1981-06-24	Decaprenylamine derivatives
TW438797B (en)	2001-06-07	Triazine containing anionic compounds useful as antiviral agents
NO174887B (no)	1994-04-18	Analogifremgangsmåte for fremstilling av terapeutisk aktive aryl- alkyl-pyrrol-2-carboxylsyreforbindelser
US5475028A (en)	1995-12-12	2-aminoethanesulfonic acid zinc complex
CN121622690B (zh)	2026-04-21	6-甲基腺嘌呤在制备抗铜绿假单胞菌感染药物中的应用
JPH0128736B2 (de)	1989-06-05